Medication Monitor



Generic Name (Trade Name—Company)
Notes
January 1, 2011

Eribulin

(Halaven—Eisai)
Nontaxane OK'd for metastatic breast cancer

Uses:

Treatment of metastatic breast cancer

Eribulin is a nontaxane microtubule dynamics inhibitor indicated for patients who have previously received at least two chemotherapeutic regimens for treatment of their metastatic breast cancer. The recommended dose is 1.4 mg/m2 given I.V. over 2 to 5 minutes on days 1 and 8 of a 21-day cycle. FDA approved the drug based on data from an open-label trial showed that treatment with eribulin improved overall survival compared with a control treatment regimen, resulting in a median response duration of 4.2 months. Common adverse events observed with therapy were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation.